An affordable new BRCA gene test has hit the market, but who should take it? — -- A new genetic testing kit that hits the market today is the most affordable, and arguably one of the simplest, ...

Experts discuss the necessity of ESR1 mutation testing when considering treatment with elacestrant in patients with estrogen receptor–positive (ER+)/HER2-negative (HER2–) metastatic breast cancer and ...

Cancer treatment has evolved from a generalised approach to a more precise one. Advances in precision medicine have transformed the way oncologists diagnose, stage, and treat cancer. At the core of ...

Mutation testing is a fault-based software validation technique that involves introducing small, systematic changes (or “mutants”) into programme code to assess the capability of test suites in ...

The standard of care for newly diagnosed hormone receptor (HR)-positive, human epidermal growth factor receptor-2 (HER2)-negative metastatic breast cancer is typically endocrine therapy in combination ...

Integrating HER2-directed therapies into NSCLC decision-making requires adapting protocols and ensuring timely updates as new therapies emerge. Streamlined processes and enhanced communication among ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...

KIT-exon-11 mutations in GISTs correlate with higher partial response rates and improved surgical outcomes with neoadjuvant Gleevec. Non-KIT exon 11 mutations and wild-type KIT/PDGFRA GISTs show less ...